Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      • Home
      • Farhat Nasim

      Articles By : Farhat Nasim

      Merck loses bid to revive over Rs 18 crore patent verdict against Gilead

      Merck loses bid to revive over Rs 18 crore patent verdict against Gilead

      Farhat Nasim31 Oct 2019 3:27 PM IST
      In 2016, a jury returned a verdict that Gilead Science's hepatitis C drugs Sovaldi and Harvoni infringed the patent, which Merck acquired when it...
      JnJ enters series of new collaborations with Government, NGOs for ending TB in India by 2025

      JnJ enters series of new collaborations with Government, NGOs for ending TB in India by 2025

      Farhat Nasim31 Oct 2019 12:39 PM IST
      Hyderabad: Johnson & Johnson(JnJ) recently announced the expansion of its tuberculosis (TB) program in India in advance of the 50th Union World...
      AstraZeneca sells European rights for schizophrenia drug Seroquel, Seroquel XR for USD 178 million

      AstraZeneca sells European rights for schizophrenia drug Seroquel, Seroquel XR for USD 178 million

      Farhat Nasim30 Oct 2019 5:25 PM IST
      The treatment, Seroquel, and another version, Seroquel XR, have lost patent protection in Europe and Russia, AstraZeneca said. The drug variants are...
      CDSCO declares 21 drug samples Not of Standard Quality

      CDSCO declares 21 drug samples Not of Standard Quality

      Farhat Nasim29 Oct 2019 4:07 PM IST
      New Delhi: Apex drug regulatory body, the Central Drugs Standard Control Organization (CDSCO) has declared batches of 21 drugs made by certain...
      Biocon bags sixth place in Global Biotech Employers ranking for 2019

      Biocon bags sixth place in Global Biotech Employers ranking for 2019

      Farhat Nasim29 Oct 2019 11:30 AM IST
      Kiran Mazumdar Shaw, CMD, Biocon said: "We have consciously created a culture that encourages ideation, experimentation and collaboration to address...
      Dr Reddys Srikakulam plant gets 4 USFDA observations

      Dr Reddys Srikakulam plant gets 4 USFDA observations

      Farhat Nasim29 Oct 2019 10:00 AM IST
      The audit of Dr Reddy's API Srikakulam Plant (SEZ) by the United States Food and Drug Administration (USFDA) was completed on Friday, the...
      New tuberculosis treatment to be available in India at Rs 73572

      New tuberculosis treatment to be available in India at Rs 73572

      Farhat Nasim29 Oct 2019 9:32 AM IST
      New Delhi: A newly-approved three-drug treatment for tuberculosis will be available in 150 countries including India and South Africa, priced at...
      Macleods Pharma recalls diabetes drug Pioglitazone Hydrochloride tablets in US

      Macleods Pharma recalls diabetes drug Pioglitazone Hydrochloride tablets in US

      Farhat Nasim29 Oct 2019 9:30 AM IST
      Pioglitazone Hydrochloride tablets being recalled are in the strength of 15 mg and have been manufactured by Macleods Pharmaceuticals in its Baddi...
      Synthetic stimulant drug Mephedrone worth Rs 3.5 crore seized from Rajdhani Express, 2 held

      Synthetic stimulant drug Mephedrone worth Rs 3.5 crore seized from Rajdhani Express, 2 held

      Farhat Nasim29 Oct 2019 9:20 AM IST
      The Directorate of Revenue Intelligence official said a team, acting on a tip-off, boarded the Mumbai-bound Rajdhani Express on Saturday morning and...
      CDSCO committee tells Roche to submit Phase III clinical trial data of blood cancer combo drug

      CDSCO committee tells Roche to submit Phase III clinical trial data of blood cancer combo drug

      Farhat Nasim27 Oct 2019 11:30 AM IST
      New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO), recently recommended drugmaker,...
      Dr Reddys gets CDSCO Committee recommendation for approval for additional indications of Desosumab

      Dr Reddys gets CDSCO Committee recommendation for approval for additional indications of Desosumab

      Farhat Nasim26 Oct 2019 2:38 PM IST
      Recently, the Hyderabad-based Dr Reddy's Labs presented its proposal before the CDSCO Committee for an additional indication for Denosumab 120...
      Drug Alert: CDSCO declares 28 samples including Soframycin, Ranitidine as sub-standard in quality; Details

      Drug Alert: CDSCO declares 28 samples including Soframycin, Ranitidine as sub-standard in quality; Details

      Farhat Nasim24 Oct 2019 2:22 PM IST
      New Delhi: Apex drug regulatory body, the Central Drugs Standard Control Organization (CDSCO) has declared batches of 28 drugs made by certain...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok